Key terms
About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NTLA news
Apr 18
11:18am ET
Biotech Alert: Searches spiking for these stocks today
Apr 15
4:32pm ET
Intellia Therapeutics Welcomes New Principal Accounting Officer
Apr 08
9:50pm ET
Analysts Offer Insights on Healthcare Companies: Pacira Pharmaceuticals (PCRX), Legend Biotech (LEGN) and Intellia Therapeutics (NTLA)
Mar 22
9:42am ET
Intellia Ends Gene Editing Deal with Regeneron Pharmaceuticals
Mar 18
7:38am ET
Intellia Therapeutics announces first patient dosed in Phase 3 MAGNITUDE study
Mar 04
12:20am ET
5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024
Feb 27
7:48am ET
Intellia Therapeutics (NTLA) Gets a Buy from Truist Financial
Feb 26
8:10am ET
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)
Feb 26
7:10am ET
Analysts Conflicted on These Healthcare Names: Cencora (COR), Alkermes (ALKS) and Intellia Therapeutics (NTLA)
Feb 25
11:36pm ET
Hold Rating for Intellia Therapeutics Amid Clinical Trials and Competitive Dynamics
Feb 25
11:30pm ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 25
11:30pm ET
Buy Rating Affirmed for Intellia Therapeutics on Strong Clinical Execution and Financial Health
Feb 24
10:16am ET
Intellia Expands At-The-Market Offering Program with Jefferies
Feb 23
9:25am ET
Intellia Therapeutics: A Measured Hold Amid Competitive and Timeline Challenges
Feb 23
9:18am ET
Intellia Therapeutics downgraded to Neutral from Buy at Goldman Sachs
Feb 23
8:47am ET
Intellia Therapeutics price target lowered to $64 from $78 at Guggenheim
Feb 23
7:38am ET
Strong Buy Rating for Intellia Therapeutics Amid Positive Trial Updates and Robust Financial Standing
Feb 23
7:38am ET
Intellia Therapeutics: A Buy Rating with Increased Price Target Amidst Strong Pipeline Progress and Financial Stability
Feb 23
7:22am ET
Intellia Therapeutics price target raised to $73 from $72 at Canaccord
Feb 23
7:19am ET
RBC Capital Sticks to Their Buy Rating for Intellia Therapeutics (NTLA)
Feb 23
3:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Tandem Diabetes Care (TNDM)
Feb 23
12:16am ET
Intellia Therapeutics: Hold Rating Maintained Amid Fair Valuation and Anticipated Clinical Milestones
Feb 22
2:50pm ET
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Intra-Cellular Therapies (ITCI)
Feb 22
7:35am ET
Intellia Therapeutics reports Q4 EPS ($1.46), consensus ($1.45)
Feb 16
7:32am ET
Buy Rating for Intellia Therapeutics: Strategic CF Therapy Partnership Enhances Pipeline and Promises Growth
Feb 16
7:14am ET
Intellia Therapeutics price target lowered to $24 from $38 at Baird
Feb 15
7:43am ET
Intellia Therapeutics, ReCode Therapeutics to develop genomic medicines for CF
Feb 15
7:36am ET
Intellia Therapeutics, ReCode Therapeutics announce collaboration
Feb 14
7:23pm ET
Intellia Therapeutics initiated with a Peer Perform at Wolfe Research
Feb 14
4:16pm ET
Intellia Therapeutics initiated with a Peer Perform at Wolfe Research
Feb 05
8:04pm ET
Cathie Wood’s ARK Investment bought 131K shares of Intellia Therapeutics today
NTLA Financials
Key terms
Ad Feedback
NTLA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NTLA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range